Puma Biotechnology Inc (NYSE:PBYI) has received an average rating of “Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $112.13.

Several equities analysts have recently weighed in on the stock. BidaskClub raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. Bank of America Corporation reissued a “buy” rating and issued a $117.00 price target (up from $100.00) on shares of Puma Biotechnology in a research note on Friday, July 21st. Cowen and Company reissued an “outperform” rating and issued a $120.00 price target (up from $91.00) on shares of Puma Biotechnology in a research note on Saturday, July 22nd. Finally, Leerink Swann restated an “outperform” rating and set a $125.00 price objective (up from $115.00) on shares of Puma Biotechnology in a research report on Wednesday, July 19th.

Shares of Puma Biotechnology (NYSE PBYI) traded down 0.81% during trading on Tuesday, reaching $79.40. 265,527 shares of the company traded hands. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $98.85. The stock’s market capitalization is $2.94 billion. The firm has a 50 day moving average of $88.37 and a 200 day moving average of $57.02.

Puma Biotechnology (NYSE:PBYI) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78. On average, equities analysts predict that Puma Biotechnology will post ($8.62) EPS for the current year.

WARNING: “Puma Biotechnology Inc (PBYI) Receives Average Rating of “Buy” from Analysts” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/15/puma-biotechnology-inc-pbyi-receives-average-rating-of-buy-from-analysts.html.

In other Puma Biotechnology news, major shareholder Adage Capital Partners Gp, L.L sold 1,235,700 shares of Puma Biotechnology stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $75.38, for a total transaction of $93,147,066.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Richard Paul Bryce sold 5,000 shares of Puma Biotechnology stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $87.10, for a total transaction of $435,500.00. Following the sale, the senior vice president now owns 34,237 shares of the company’s stock, valued at $2,982,042.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,010,261 shares of company stock valued at $159,425,452. 22.70% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in PBYI. Norges Bank bought a new stake in shares of Puma Biotechnology during the fourth quarter worth $7,693,000. Emerald Advisers Inc. PA bought a new stake in shares of Puma Biotechnology during the first quarter worth $14,110,000. BB Biotech AG boosted its stake in shares of Puma Biotechnology by 1.5% in the first quarter. BB Biotech AG now owns 245,616 shares of the biopharmaceutical company’s stock worth $9,137,000 after buying an additional 3,625 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Puma Biotechnology during the first quarter worth $7,682,000. Finally, American International Group Inc. boosted its stake in shares of Puma Biotechnology by 19.2% in the first quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock worth $630,000 after buying an additional 2,733 shares in the last quarter. Institutional investors and hedge funds own 80.98% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.